Nanomedicine for ovarian cancer: Enhancing pharmacokinetics and biodistribution

Ovarian cancer continues to pose a substantial healthcare obstacle, demanding the development of novel strategies to improve therapeutic results. Nanomedicine’s introduction has created novel opportunities for the targeted delivery of drugs in the treatment of ovarian cancer. This review article presents a thorough examination of the pharmacokinetics and biodistribution of nanoparticles designed to target ovarian cancer, emphasizing their capacity to significantly transform therapeutic approaches. Furthermore, we investigate the function of nanoparticles as vehicles for precise pharmaceutical administration, placing particular emphasis on the benefits they offer in comparison to traditional methodologies. We explore the intricacies of biodistribution, including the influence of formulations, surface modifications, and nanoparticle size on their internal distribution. In addition, we provide a comprehensive analysis of the importance of pharmacokinetics in the enhancement of drug delivery. This includes a synopsis of critical parameters including absorption, distribution, metabolism, and excretion, and their connection to the therapeutic effectiveness of nanoparticle-based approaches for ovarian cancer. A fundamental component of this review is a critical evaluation of the approaches utilized to improve the biodistribution and pharmacokinetics of nanoparticles designed to target ovarian cancer. Moreover, we have highlighted significant research studies and clinical trials of the in vivo behavior of nanoparticles and their practical applications. Nevertheless, we refrain from obfuscating over the extant obstacles and constraints, such as possible toxicity issues and impediments to the process of clinical translation. The paper concludes by engaging in a discussion on emerging technologies and future prospects, with a specific emphasis on the potential of personalized medicine in the context of ovarian cancer treatment.